Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corporate Update Conference Call & Webcast Announcement

T.RVX

TSX Exchange Symbol: RVX

CALGARY, Oct. 1, 2014 /CNW/ - Resverlogix Corp. (TSX:RVX) will be hosting a corporate update conference call and webcast on Monday, October 6, 2014 at 11 am MDT / 1 pm ET.

Details for the conference call and webcast are as follows:

Link to webcast: http://services.choruscall.ca/links/resverlogix141006.html

Dial in numbers:
Canada & USA Toll Free Dial In: 1-800-319-4610
Outside of Canada & USA call: +1-604-638-5340  

About Resverlogix

Resverlogix Corp. (TSX: RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-I. RVX-208 is a first-in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

Company Contacts:      
       
Donald J. McCaffrey       Sarah Zapotichny   
President and CEO       Director, Investor Relations
Resverlogix Corp.        Resverlogix Corp.
Phone: 403-254-9252        Phone: 403-254-9252
Email: don@resverlogix.com      Email: sarah@resverlogix.com
     

 

SOURCE Resverlogix Corp.

Copyright CNW Group 2014